Literature DB >> 12357534

Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model.

Gishel New1, Jeffrey W Moses, Gary S Roubin, Martin B Leon, Antonio Colombo, Sriram S Iyer, Fermin O Tio, Roxana Mehran, Nicholas Kipshidze.   

Abstract

Estrogen can inhibit intimal proliferation and accelerate endothelial regeneration after angioplasty. This suggests that estrogen may prevent in-stent restenosis. Unlike other therapies to prevent restenosis, estrogen may also not delay endothelial regrowth, thereby avoiding the risk of late stent thrombosis. The purpose of this work was to determine the effect of a 17beta-estradiol-eluting stent on neointimal formation in a porcine model. Each artery of six pigs was randomized to either a control, low-dose, or high-dose 17beta-estradiol-eluting stent. All animals were sacrificed at 30 days for histopathological analysis. There was a 40% reduction in intimal area in the high-dose stents compared with control stents (2.54 +/- 1.0 vs. 4.13 +/- 1.1 mm(2), for high dose vs. control, respectively; P < 0.05). There was complete endothelial regeneration at 30 days and similar inflammatory response to stenting on histopathology in all the stent groups. This is the first study to show that 17beta-estradiol-eluting stents are associated with reduced neointimal formation without affecting endothelial regeneration in the pig model of in-stent restenosis. Estrogen-coated stents may have a potential benefit in the prevention and treatment of in-stent restenosis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12357534     DOI: 10.1002/ccd.10339

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  9 in total

Review 1.  Drug-eluting stents for cardiovascular disorders.

Authors:  Juan F Granada; Grzegorz L Kaluza; Albert Raizner
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

Review 2.  Coronary stents: in these days of climate change should all stents wear coats?

Authors:  R Lowe; I B A Menown; G Nogareda; I M Penn
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 3.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 4.  GPER-novel membrane oestrogen receptor.

Authors:  Margaret A Zimmerman; Rebecca A Budish; Shreya Kashyap; Sarah H Lindsey
Journal:  Clin Sci (Lond)       Date:  2016-06-01       Impact factor: 6.124

Review 5.  [When are drug-eluting stents effective? A critical analysis of the presently available data].

Authors:  S Silber
Journal:  Z Kardiol       Date:  2004-09

Review 6.  Biomaterials and advanced technologies for the evaluation and treatment of ovarian aging.

Authors:  Meng Wu; Yican Guo; Simin Wei; Liru Xue; Weicheng Tang; Dan Chen; Jiaqiang Xiong; Yibao Huang; Fangfang Fu; Chuqing Wu; Ying Chen; Su Zhou; Jinjin Zhang; Yan Li; Wenwen Wang; Jun Dai; Shixuan Wang
Journal:  J Nanobiotechnology       Date:  2022-08-11       Impact factor: 9.429

Review 7.  Estrogen-eluting stents.

Authors:  Sung Kee Ryu; Ehtisham Mahmud; Sotirios Tsimikas
Journal:  J Cardiovasc Transl Res       Date:  2009-05-19       Impact factor: 4.132

8.  Heparin-Tagged PLA-PEG Copolymer-Encapsulated Biochanin A-Loaded (Mg/Al) LDH Nanoparticles Recommended for Non-Thrombogenic and Anti-Proliferative Stent Coating.

Authors:  Shivakalyani Adepu; Hongrong Luo; Seeram Ramakrishna
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

Review 9.  Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.

Authors:  Rui-Xing Yin; De-Zhai Yang; Jin-Zhen Wu
Journal:  Theranostics       Date:  2014-01-08       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.